NAD+ has more clinic pages than trials. The search term "nad dosage" spans capsules, drips and the injectable vial, and the figures on those pages run from 10 mg to 1,000 mg without a label to anchor any of them. This page reports what can be checked, in the order of how well it can be checked, and then works the units for the four vial sizes the site's calculator uses.
NAD+ is nicotinamide adenine dinucleotide, a coenzyme in every human cell, made from niacin, nicotinamide riboside or tryptophan. It is not a peptide; it sits in this catalogue because it is sold and reconstituted through the same channel. Medibact's NAD+ guide covers the molecule, the precursors and the evidence; this page stays with figures. The dosage hub lists every compound's page, and Peptifact's NAD dosage page grades the same sources from a journalist's angle.
What the sources state
| Source | Kind | Figure | Date read |
|---|---|---|---|
| DailyMed search, "nicotinamide adenine dinucleotide" | Label search | Zero records; no approved NAD+ injection | 2026-09-18 |
| NCT06919328, Nutraceuticals Research Institute, started 2024-10-31, recruiting | Trial protocol | 100 mg NAD+ in 2 mL bacteriostatic water by intramuscular, subcutaneous or intravenous-push injection, against 100 mg nicotinamide riboside and against water; primary outcome pain at 1 minute; 70 planned | 2026-09-18 |
| Yu et al., American Journal of Cardiovascular Drugs 2026 (PMID 40954388) | Trial publication | 10 mg NAD+ intravenously a day for 7 days; 180 adults with ischaemic heart failure; ejection fraction improved at one month | 2026-09-18 |
| Grant et al., Frontiers in Aging Neuroscience 2019 (PMID 31572171) | Trial publication (pilot pharmacokinetics) | 3 micromoles per minute intravenously for 6 hours (about 0.7 g, this page's conversion); no plasma rise for 2 hours | 2026-09-18 |
| NCT05849519, "Coenzyme I" for sudden hearing loss, early phase 1 | Trial protocol | 5 mg intramuscularly daily | 2026-09-18 |
| Gallagher et al., Ageing Research Reviews 2026 (PMID 41655607) | Systematic review | 113 studies (33 human); parenteral NAD+ "lacks adequate clinical trial evidence" | 2026-09-18 |
| Clinic page (medical wellness clinic) | Clinic convention | Compounded 100 mg/mL; subcutaneous 10 mg daily in week 1, then 25 mg, then 50 to 100 mg two to three times a week; intramuscular 50 to 100 mg weekly; intravenous 100 to 250 mg then 500 to 1,000 mg | 2026-09-18 |
| Vendor protocol page | Commonly cited | 50 to 100 mg once daily subcutaneously; 100 to 500 mg intramuscularly or subcutaneously several times a week; 250 to 1,000 mg intravenously over 1 to 4 hours once weekly; 500 mg vial at 3 mL | 2026-09-18 |
The gap between the rows is the finding. The two trials that state a dose used 10 mg a day and a single 100 mg injection. The clinic and vendor figures run to 1,000 mg per session. Nothing in the indexed literature tests the clinic schedule, and the 2026 review says so in general terms.
Concentration is the number that changes
Compounded NAD+ is dispensed at 100 mg/mL, and the trial registration prepared it at 50 mg/mL, so a "50 mg" figure is 0.5 mL in one and 1 mL in the other. Research vials at 1 to 3 mL are mostly more concentrated than either: a 500 mg vial at 2 mL is 250 mg/mL, and a 1,000 mg vial at 1 mL is 1,000 mg/mL, ten times the clinic strength. This site's calculator note makes a point that belongs here too: scaling water with vial size leaves the concentration unchanged, so a bigger vial with proportionally more water draws exactly the same volume for a given amount; only less water per milligram makes a draw smaller.
Units per dose at each research-vial size
The table takes each of the four vial sizes at 1, 2 and 3 mL, states the concentration, and converts three figures from the record, 25 mg and 50 mg (the clinic titration steps) and 100 mg (the registered trial dose and the clinic ceiling), into U-100 syringe units, where 100 units is 1 mL (MedlinePlus, read 2026-09-18); the site's insulin syringe units page covers the syringe reading itself. The 10 mg heart-failure dose is a tenth of the 100 mg column at every row.
| Vial | Water added | Concentration | 25 mg | 50 mg | 100 mg |
|---|---|---|---|---|---|
| 100 mg | 1 mL | 100 mg/mL | 25 | 50 | 100 |
| 100 mg | 2 mL | 50 mg/mL | 50 | 100 | 200 (>1 syringe) |
| 100 mg | 3 mL | 33.3 mg/mL | 75 | 150 (>1 syringe) | 300 (>1 syringe) |
| 500 mg | 1 mL | 500 mg/mL | 5 | 10 | 20 |
| 500 mg | 2 mL | 250 mg/mL | 10 | 20 | 40 |
| 500 mg | 3 mL | 167 mg/mL | 15 | 30 | 60 |
| 750 mg | 1 mL | 750 mg/mL | 3.3 | 6.7 | 13.3 |
| 750 mg | 2 mL | 375 mg/mL | 6.7 | 13.3 | 26.7 |
| 750 mg | 3 mL | 250 mg/mL | 10 | 20 | 40 |
| 1,000 mg | 1 mL | 1,000 mg/mL | 2.5 | 5 | 10 |
| 1,000 mg | 2 mL | 500 mg/mL | 5 | 10 | 20 |
| 1,000 mg | 3 mL | 333 mg/mL | 7.5 | 15 | 30 |
The 100 mg vial is the only size at which the compounded strength appears, at 1 mL, and the only size at which the trial's preparation appears, at 2 mL; every other row is more concentrated than anything in the clinical record. The infusion figures of 250 to 1,000 mg are diluted into a bag in every source that describes them and are not shown as syringe draws. The NAD+ calculator works any combination entered; the site's NAD+ reconstitution page covers water volumes per vial and the mixing steps as references describe them.
What the figures omit
The heart-failure trial figure carries a population, a route, a daily schedule and a seven-day duration, chosen for a disease. The registered 100 mg figure carries a route and a single occasion; its purpose is to measure how much the injection hurts. The pharmacokinetic figure carries a rate and a duration in healthy adults and no repeat. The clinic and vendor figures carry a route and a frequency but no population, no endpoint and no trial; the titration ceiling on the clinic page, 50 mg per injection in 24 hours, is that clinic's rule and appears nowhere else in the record. None of the rows says what happens after the 4-to-6-week cycles vendor pages describe, because no study followed one.
What this page does not do
This page reports figures with their sources and dates and converts them into syringe units at the site's vial sizes. It does not recommend a dose, a route or a frequency for anyone, does not say whether the clinic schedule is safe, and does not turn the vendor range into advice. The mixing steps and the storage of a mixed vial are the store's topics: how to reconstitute peptides and how to store peptides on medibact.com.
Sources and dates
Opened 2026-09-18: the DailyMed SPL search API for "nicotinamide adenine dinucleotide" (zero records); the ClinicalTrials.gov v2 API for the term with intravenous, injection or subcutaneous (83 records, NCT06919328 opened in full, NCT05849519 from the listing); PubMed through the NCBI E-utilities for the abstracts of PMIDs 40954388, 31572171 and 41655607 among 20 returned by a search for intravenous NAD+ in humans; PubChem for the molecular weight (CID 5892); one clinic page and one vendor protocol page; and MedlinePlus for the U-100 definition. Not opened: FDA's nominated-bulk-substances list and the related advisory-committee document, which returned HTTP 401 and 403 on the day. Corrections go to the contact page.